Amarin Corp Plcuk (AMRN) Cash from Financing Activities (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Cash from Financing Activities of -$1.7 million for Q1 2026, down 50.76% YoY from -$3.4 million in Q1 2025, and down 42075.0% sequentially from -$4000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$1.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 50.76% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at -$2.6 million (down 129.05% YoY), while the FY2025 annual figure was -$2.0 million, down 40.96% from the prior year.
- Cash from Financing Activities declined to -$1.7 million in Q1 2026, from -$4000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for AMRN reached as high as $364000.0 in Q1 2023 and fell as low as -$1.7 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is -$68000.0 (2024), against an average of -$312529.4.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 172.08% — and 2025, when it tumbled 2050.0%.
- A 5-year view of Cash from Financing Activities shows it stood at $38000.0 in 2022, then surged by 118.42% to $83000.0 in 2023, then sank by 79.52% to $17000.0 in 2024, then tumbled by 123.53% to -$4000.0 in 2025, then sank by 42075.0% to -$1.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.7 million, -$4000.0, and -$248000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -3.47 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 530.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 919.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 267.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.69 Mn |
| Mar 31, 2026 | -1.69 Mn |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Jun 30, 2025 | -663,000.00 |
| Jun 30, 2025 | -663,000.00 |
| Mar 31, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | 17,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Mar 31, 2024 | -1.43 Mn |
| Mar 31, 2024 | -1.43 Mn |
| Dec 31, 2023 | 83,000.00 |
| Dec 31, 2023 | 83,000.00 |